Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.84 |
| ▸ | HPGD | P15428 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079157 | 0.88 | GFER (0.78) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL21933266 | 0.86 | LMNA (0.63) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL9968020 | 0.85 | HPGD (0.74) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL9968014 | 0.85 | HPGD (0.74) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL9968015 | 0.85 | HPGD (1.00) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL9968017 | 0.85 | MAPT (1.00) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL15705429 | 0.84 | LMNA (0.85) | LMNAHPGDALDH1A1MAPTPKM | |
| SCHEMBL7591707 | 0.83 | LMNA (0.63) | LMNAHPGDALDH1A1MAPTGFER | |
| SCHEMBL30926746 | 0.80 | MAPT (0.71) | LMNAHPGDALDH1A1MAPTMEN1 | |
| SCHEMBL1791457 | 0.80 | MAPT (0.84) | LMNAHPGDALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012082862-A2 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088187-A1 | ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF | AR, NR5A1, ESRRB | LMNA 3911/4885HPGD 917/4885ALDH1A1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.